A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

780

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

BIOLOGICAL: Sacituzumab tirumotecan
BIOLOGICAL: Pembrolizumab
DRUG: Cisplatin
DRUG: Pemetrexed
DRUG: Gemcitabine
DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: Rescue medication

Sponsor

Merck Sharp & Dohme LLC